Anteris Locks in 181,000 Sq Ft Minnesota Facility to Support US Expansion
Anteris Technologies (NASDAQ: AVR, ASX: AVR) has entered a lease agreement for approximately 181,436 square feet of office and warehouse space in Brooklyn Park, Minnesota, through its wholly-owned subsidiary Anteris Technologies Corporation. The lease, executed on 23 April 2026, represents a significant infrastructure commitment as the dual-listed structural heart company scales its US commercial operations.
Key terms of the Brooklyn Park lease
The lease with landlord Northcross West Industrial Owner, LLC establishes a substantial long-term facility commitment in Minnesota’s medical device corridor.
| Term | Detail |
|---|---|
| Facility size | Approximately 181,436 sq ft |
| Location | Brooklyn Park, Minnesota |
| Lease commencement | 1 September 2026 |
| Initial term expiry | 31 August 2037 |
| Initial monthly rent | US$152,708.63 |
| Extension options | Two periods of 84 months each at market rent |
The lease structure includes a rent abatement arrangement: the first three months are fully abated provided the company remains in compliance, with the succeeding nine months partially abated. Monthly rent is subject to annual escalations plus real estate taxes, operating expenses, and other charges.
The abatement structure reduces initial cash outlay during the facility fit-out period, preserving capital for operational priorities.
When big ASX news breaks, our subscribers know first
What is a material definitive agreement and why it matters
A “material definitive agreement” in SEC reporting context refers to a binding contract that could materially affect a company’s business operations or financial position. Public companies listed on US exchanges must file Form 8-K current reports when entering such agreements, providing investors with timely disclosure of significant corporate commitments.
The requirement to file this lease as a material agreement signals its financial and strategic significance. This is not a routine operational expense—it represents a substantive long-term commitment that Anteris management and legal counsel determined meets the SEC’s materiality threshold for immediate disclosure.
The SEC filing requirement indicates this lease represents a substantive long-term commitment, not a routine operational expense.
Strategic fit with Anteris’ US operations
Anteris already maintains a significant presence in Minneapolis, with an existing facility at 860 Blue Gentian Road in Eagan, Minnesota. The Brooklyn Park facility expands upon this established US footprint within the same metropolitan region, which hosts a concentration of medical device industry infrastructure and talent.
Consolidating operations in the Minneapolis region may create operational efficiencies and proximity to medical device industry infrastructure.
Anteris’ DurAVR THV and the path to commercialisation
Anteris’ lead product, the DurAVR® THV, is a biomimetic transcatheter heart valve designed to treat aortic stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable valve is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow.
The DurAVR® THV uses ADAPT® tissue, Anteris’ patented anti-calcification tissue technology. ADAPT® tissue is FDA-cleared and has been used clinically for over 10 years, distributed for use in more than 55,000 patients worldwide. The DurAVR® THV System comprises the valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System.
The safety and efficacy of the DurAVR® THV are currently being evaluated in the PARADIGM Trial (NCT07194265), with first patients enrolled and implanted in Denmark during the fourth quarter of 2025.
The announcement does not explicitly link the new facility to DurAVR manufacturing. However, the facility expansion supports broader US operations, which may include manufacturing capacity as the company progresses toward potential commercialisation.
Expanded US infrastructure positions Anteris to scale operations if clinical trial results support regulatory approval and commercial launch.
Financial commitment profile
The Brooklyn Park lease establishes the following financial obligations:
- Initial monthly rent: US$152,708.63
- Lease term: 11 years (September 2026 to August 2037)
- Potential extensions: up to 14 additional years (two 84-month periods)
- Additional costs: real estate taxes, operating expenses, other charges
The total potential lease commitment spans up to 25 years if both extension options are exercised.
Long-term lease commitments demonstrate management confidence in sustained US operational requirements.
The next major ASX story will hit our subscribers first
What this means for AVR shareholders
The Brooklyn Park facility lease signals Anteris’ commitment to building physical infrastructure capable of supporting potential US commercialisation activities. The expanded capacity beyond the existing Eagan facility, combined with the 11-year initial lease term, indicates management’s operational planning horizon extends well beyond near-term clinical trial milestones.
The filing was authorised for release by Vice Chairman and Chief Executive Officer Wayne Paterson. Anteris shareholders can monitor upcoming Form 10-Q filings for the three months ended 31 March 2026, where the full lease text will be filed as an exhibit, providing complete commercial terms and conditions.
Want Healthcare Breakthroughs in Your Inbox Before the Market Moves?
Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to get market-moving announcements delivered straight to your inbox the moment they break.